Wright Medical launches injectable bone graft worldwide:
This article was originally published in Clinica
Wright Medical has launched worldwide its Pro-dense injectable regenerative graft, a bone graft substitute. While the product received US FDA approval in February 2006, it was released in a controlled fashion to select institutions to confirm human effectiveness over a 17-month period, said the Arlington, Tennessee firm. "Extra time and resources were invested in order to generate strong clinical experience prior to our full-scale commercial release," said John Treace, VP of marketing for Wright's biologics division. Studies have shown that when bone voids are treated with Pro-dense, new bone tissue formed at a faster rate than with autograft - widely considered to be the gold standard, claimed the firm.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.